The drug remains in Phase 3 clinical trials (see ClinicalTrials
Supplementation ensures that EPA and DHA levels remain adequate for brain function, cardiovascular protection, and inflammation management
You can typically resume GLP-1 therapy once you're tolerating a normal diet without nausea or vomiting, normal bowel function has returned, and your surgical team approves
Back Patchen, T (8 March 2024) 'FDA approves novo's obesity drug Wegovy to reduce cardiovascular events', Biospace
Given the effects on human metabolism, long-term use raises questions about how these treatments may reshape metabolic function, beyond therapy duration
Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects